Uganda begin Ebola Virus Vaccine Trial after new outbreak That killed a nurse in Kampala
Quote from Alex bobby on February 3, 2025, 2:42 AM
Uganda Prepares for Trial Vaccine Deployment Amid Kampala Ebola Outbreak
Ugandan health officials are accelerating efforts to deploy a trial vaccine in response to a newly confirmed outbreak of the Sudan strain of Ebola in the capital, Kampala. The move comes after the virus claimed the life of a nurse employed at the city’s main referral hospital. The outbreak was officially declared by authorities the day after the nurse's death, prompting swift action from Uganda’s Ministry of Health and global health organisations.
Fast-Tracking Vaccine Deployment
Pontiano Kaleebu, Executive Director of the Uganda Virus Research Institute (UVRI), announced that research protocols are being expedited to facilitate the deployment of over 2,000 doses of a candidate vaccine. “Protocol is being accelerated to get all the necessary regulatory approvals,” Kaleebu stated, emphasising that the vaccine has not yet been licensed.
The World Health Organisation (WHO) has pledged its support by ensuring Uganda has access to 2,160 doses of the trial vaccine. In a statement, WHO confirmed that research teams have already been deployed to work alongside surveillance teams while awaiting approval.
Currently, there are no licensed vaccines for the Sudan strain of Ebola, making this trial a crucial step in preventing further spread of the disease. The vaccine’s manufacturer has not yet been identified, but health experts are optimistic that this trial could be instrumental in future outbreak responses.
Tracing the Source and Contacts
Authorities are still investigating the origins of the current outbreak. As of now, no additional confirmed cases have been reported. However, tracing and monitoring contacts is essential to containing the spread. Uganda’s Ministry of Health has identified at least 44 contacts of the deceased nurse, including 30 health workers and hospital patients.
Given Kampala’s high population density and mobility—home to approximately 4 million residents—officials fear the virus could spread rapidly if not contained. The deceased nurse had sought medical treatment at multiple facilities, including a hospital outside Kampala and another in Mbale, in the country’s east. Health authorities also confirmed that the nurse consulted a traditional healer before his passing, raising concerns about potential transmission through multiple regions.
Uganda’s Ebola History and Vaccine Efforts
Uganda has faced multiple Ebola outbreaks in the past, including a devastating one in 2000 that resulted in hundreds of deaths. More recently, an Ebola outbreak in central Uganda between 2022 and 2023 claimed at least 55 lives. Though Ugandan officials had access to candidate vaccine doses, the outbreak ended before vaccine trials could commence.
One of the most successful vaccines against Ebola, known as rVSV-ZEBOV, was previously used to vaccinate 3,000 people at risk during the 2018-2020 outbreak of the Zaire strain in eastern Congo. The vaccine proved effective in halting the spread of the virus. However, this vaccine does not protect against the Sudan strain currently affecting Uganda, necessitating the urgent trial of a new vaccine.
Regional Outbreaks and Concerns
Kampala’s Ebola outbreak is part of a concerning pattern of viral hemorrhagic fever outbreaks across East Africa. In March, Tanzania declared an outbreak of Marburg virus, a disease closely related to Ebola. Meanwhile, Rwanda recently announced the end of its own Marburg outbreak. The ongoing Marburg outbreak in Tanzania’s Kagera region has already claimed at least two lives, according to local health officials.
Public health experts warn that the continued emergence of such diseases across the region underscores the importance of coordinated response strategies and investment in medical research.
Challenges in Controlling the Spread
Containing an Ebola outbreak in a densely populated urban setting like Kampala presents significant challenges. Unlike previous outbreaks that were often concentrated in remote areas, the mobility of residents in the capital increases the risk of widespread transmission.
The Ebola virus is transmitted through direct contact with bodily fluids of an infected person or contaminated materials. Common symptoms include fever, vomiting, diarrhea, muscle pain, and, in severe cases, internal and external bleeding. Early detection, isolation of suspected cases, and swift medical intervention are critical to controlling the spread.
Scientists have yet to determine the natural reservoir of Ebola, but it is widely believed that the virus is transmitted to humans through contact with infected animals, such as fruit bats or non-human primates. Consuming raw or undercooked meat from infected animals is also considered a potential risk factor.
Conclusion
Uganda’s rapid response to the Kampala Ebola outbreak, including the expedited deployment of a trial vaccine, highlights the country’s commitment to containing the virus and preventing further casualties. While the vaccine’s effectiveness against the Sudan strain remains to be determined, the trial presents a crucial opportunity for advancing Ebola treatment and prevention efforts.
With support from WHO and other global health organisations, Uganda’s health officials continue to prioritise contact tracing, public awareness campaigns, and regulatory approvals to facilitate vaccine distribution. However, given the high mobility of Kampala’s population, continued vigilance and swift intervention will be essential to curbing the outbreak and preventing further spread.
As East Africa grapples with recurring outbreaks of Ebola and Marburg, the need for investment in research, vaccine development, and regional collaboration has never been greater. The success of Uganda’s trial vaccine could provide a much-needed breakthrough in the fight against Ebola, potentially saving countless lives in the region and beyond.
Uganda Prepares for Trial Vaccine Deployment Amid Kampala Ebola Outbreak
Ugandan health officials are accelerating efforts to deploy a trial vaccine in response to a newly confirmed outbreak of the Sudan strain of Ebola in the capital, Kampala. The move comes after the virus claimed the life of a nurse employed at the city’s main referral hospital. The outbreak was officially declared by authorities the day after the nurse's death, prompting swift action from Uganda’s Ministry of Health and global health organisations.
Fast-Tracking Vaccine Deployment
Register for Tekedia Mini-MBA edition 16 (Feb 10 – May 3, 2025) today for early bird discounts.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register to become a better CEO or Director with Tekedia CEO & Director Program.
Pontiano Kaleebu, Executive Director of the Uganda Virus Research Institute (UVRI), announced that research protocols are being expedited to facilitate the deployment of over 2,000 doses of a candidate vaccine. “Protocol is being accelerated to get all the necessary regulatory approvals,” Kaleebu stated, emphasising that the vaccine has not yet been licensed.
The World Health Organisation (WHO) has pledged its support by ensuring Uganda has access to 2,160 doses of the trial vaccine. In a statement, WHO confirmed that research teams have already been deployed to work alongside surveillance teams while awaiting approval.
Currently, there are no licensed vaccines for the Sudan strain of Ebola, making this trial a crucial step in preventing further spread of the disease. The vaccine’s manufacturer has not yet been identified, but health experts are optimistic that this trial could be instrumental in future outbreak responses.
Tracing the Source and Contacts
Authorities are still investigating the origins of the current outbreak. As of now, no additional confirmed cases have been reported. However, tracing and monitoring contacts is essential to containing the spread. Uganda’s Ministry of Health has identified at least 44 contacts of the deceased nurse, including 30 health workers and hospital patients.
Given Kampala’s high population density and mobility—home to approximately 4 million residents—officials fear the virus could spread rapidly if not contained. The deceased nurse had sought medical treatment at multiple facilities, including a hospital outside Kampala and another in Mbale, in the country’s east. Health authorities also confirmed that the nurse consulted a traditional healer before his passing, raising concerns about potential transmission through multiple regions.
Uganda’s Ebola History and Vaccine Efforts
Uganda has faced multiple Ebola outbreaks in the past, including a devastating one in 2000 that resulted in hundreds of deaths. More recently, an Ebola outbreak in central Uganda between 2022 and 2023 claimed at least 55 lives. Though Ugandan officials had access to candidate vaccine doses, the outbreak ended before vaccine trials could commence.
One of the most successful vaccines against Ebola, known as rVSV-ZEBOV, was previously used to vaccinate 3,000 people at risk during the 2018-2020 outbreak of the Zaire strain in eastern Congo. The vaccine proved effective in halting the spread of the virus. However, this vaccine does not protect against the Sudan strain currently affecting Uganda, necessitating the urgent trial of a new vaccine.
Regional Outbreaks and Concerns
Kampala’s Ebola outbreak is part of a concerning pattern of viral hemorrhagic fever outbreaks across East Africa. In March, Tanzania declared an outbreak of Marburg virus, a disease closely related to Ebola. Meanwhile, Rwanda recently announced the end of its own Marburg outbreak. The ongoing Marburg outbreak in Tanzania’s Kagera region has already claimed at least two lives, according to local health officials.
Public health experts warn that the continued emergence of such diseases across the region underscores the importance of coordinated response strategies and investment in medical research.
Challenges in Controlling the Spread
Containing an Ebola outbreak in a densely populated urban setting like Kampala presents significant challenges. Unlike previous outbreaks that were often concentrated in remote areas, the mobility of residents in the capital increases the risk of widespread transmission.
The Ebola virus is transmitted through direct contact with bodily fluids of an infected person or contaminated materials. Common symptoms include fever, vomiting, diarrhea, muscle pain, and, in severe cases, internal and external bleeding. Early detection, isolation of suspected cases, and swift medical intervention are critical to controlling the spread.
Scientists have yet to determine the natural reservoir of Ebola, but it is widely believed that the virus is transmitted to humans through contact with infected animals, such as fruit bats or non-human primates. Consuming raw or undercooked meat from infected animals is also considered a potential risk factor.
Conclusion
Uganda’s rapid response to the Kampala Ebola outbreak, including the expedited deployment of a trial vaccine, highlights the country’s commitment to containing the virus and preventing further casualties. While the vaccine’s effectiveness against the Sudan strain remains to be determined, the trial presents a crucial opportunity for advancing Ebola treatment and prevention efforts.
With support from WHO and other global health organisations, Uganda’s health officials continue to prioritise contact tracing, public awareness campaigns, and regulatory approvals to facilitate vaccine distribution. However, given the high mobility of Kampala’s population, continued vigilance and swift intervention will be essential to curbing the outbreak and preventing further spread.
As East Africa grapples with recurring outbreaks of Ebola and Marburg, the need for investment in research, vaccine development, and regional collaboration has never been greater. The success of Uganda’s trial vaccine could provide a much-needed breakthrough in the fight against Ebola, potentially saving countless lives in the region and beyond.
Uploaded files: